首页> Lung cancer (Amsterdam, Netherlands)> A phase I study of binimetinib (MEK 162), a MEK inhibitor, plus carboplatin and pemetrexed chemotherapy in non-squamous non-small cell lung cancer.

A phase I study of binimetinib (MEK 162), a MEK inhibitor, plus carboplatin and pemetrexed chemotherapy in non-squamous non-small cell lung cancer.

导出 LinkOut

翻译打印收藏纠错

第一作者： A S,Fung

第一单位： Department of Oncology, Queen's University, Canada; Princess Margaret Cancer Centre, University Health Network, Canada.

作者： A S,Fung ^[1] ; D M,Graham ^[2] ; E X,Chen ^[3] ; T L,Stockley ^[4] ; T,Zhang ^[5] ; L W,Le ^[6] ; H,Albaba ^[6] ; K M,Pisters ^[7] ; P A,Bradbury ^[3] ; M,Trinkaus ^[8] ; M,Chan ^[9] ; S,Arif ^[9] ; U,Zurawska ^[10] ; J,Rothenstein ^[11] ; D,Zawisza ^[6] ; S,Effendi ^[6] ; S,Gill ^[6] ; M,Sawczak ^[6] ; J H,Law ^[6] ; N B,Leighl ^[12]

作者单位： Department of Oncology, Queen's University, Canada; Princess Margaret Cancer Centre, University Health Network, Canada. ^[1] Princess Margaret Cancer Centre, University Health Network, Canada; Division of Medical Oncology, University of Toronto, Canada; The Christie NHSFoundation Trust, Manchester, UK. ^[2] Princess Margaret Cancer Centre, University Health Network, Canada; Division of Medical Oncology, University of Toronto, Canada. ^[3] Division of Clinical Laboratory Genetics, University Health Network, Canada; Department of Laboratory Medicine and Pathobiology, University of Toronto, Canada; Advanced Molecular Diagnostics Laboratory, University Health Network, Canada. ^[4] Division of Clinical Laboratory Genetics, University Health Network, Canada; Advanced Molecular Diagnostics Laboratory, University Health Network, Canada. ^[5] Princess Margaret Cancer Centre, University Health Network, Canada. ^[6] Princess Margaret Cancer Centre, University Health Network, Canada; MD Anderson Cancer Centre, Houston, TX, United States. ^[7] Division of Medical Oncology, University of Toronto, Canada; Markham Stouffville Hospital, Markham, Canada. ^[8] Division of Medical Oncology, University of Toronto, Canada; Trillium Health Partners, Mississauga, Canada. ^[9] Division of Medical Oncology, University of Toronto, Canada; St. Joseph's Health Centre, Toronto, Canada. ^[10] Division of Medical Oncology, University of Toronto, Canada; RS McLaughlin Durham Cancer Centre, Oshawa, Canada. ^[11] Princess Margaret Cancer Centre, University Health Network, Canada; Division of Medical Oncology, University of Toronto, Canada. Electronic address: Natasha.Leighl@uhn.ca. ^[12]

关键词 Binimetinib Carboplatin NSCLC Pemetrexed Phase I